Future Outlook of Advanced Ovarian Cancer Treatment
Comprehensive insights on unmet needs, ongoing research, and the future of advanced ovarian cancer treatment.
Advanced Ovarian Cancer: Current Treatment Landscape in Second- and Later-Line Settings
Expert oncologists review the current PARP inhibitor treatment indications for patients with advanced ovarian cancer and discuss how to best manage patients who have been impacted by the recent updates to the PARP inhibitors.
Advanced Ovarian Cancer: Updated Indications for PARP Inhibitors in Second- and Later-Line Settings
Drs Coleman and Monk discuss what led to the recent withdrawal of several indications for PARP inhibitors in the treatment of advanced ovarian cancer.
Role of PARP Inhibitors in Advanced Ovarian Cancer
Expert oncologists give an overview of PARP inhibitors available for the treatment of patients with advanced ovarian cancer and review adverse events seen with each agent.
Role of Biomarkers in Advanced Ovarian Cancer
Experts on advanced ovarian cancer give detailed insights on the role of biomarker testing and identify important biomarkers.
Overview of Advanced Ovarian Cancer
Robert L Coleman, MD, FACOG, FACS, and Bradley J Monk, MD, FACOG, FACS, provide an overview of advanced ovarian cancer and discuss its prevalence and diagnosis process.
Dr. Monk on the Emergence of NaPi2b as a Target in Ovarian Cancer
Bradley J. Monk, MD, FACS, discusses the emergence and utility of NaPi2b as a target in ovarian cancer.
Cervical Cancer Management: Looking Toward the Future of Care
Closing out their discussion on the management of cervical cancer, panelists share their excitement for future evolutions in care.
Metastatic Cervical Cancer: Practical Considerations for Tisotumab Vedotin Use
Experts share their experience and thoughts on the use of tisotumab vedotin as the management of metastatic cervical cancer continues to evolve.
Metastatic Cervical Cancer: ADC Adverse Event Management
Considerations for adverse event management with tisotumab vedotin use in patients with metastatic cervical cancer.
Tisotumab Vedotin: A Second-Line ADC Approval in Metastatic Cervical Cancer
Shared insight on the approval of tisotumab vedotin, an antibody-drug conjugate, in the second-line setting of metastatic cervical cancer.
Metastatic Cervical Cancer: Moving Immune Checkpoint Inhibition to the Front Line
Panelists reflect on the potential for immune checkpoint inhibition to become a frontline option in metastatic cervical cancer, and what that means for the second-line setting.
Second-Line Immune Checkpoint Inhibition in Metastatic Cervical Cancer
An overview of second-line immune checkpoint inhibitor use in patients with relapsed or refractory metastatic cervical cancer.
Unmet Needs in Second-Line Therapy for Metastatic Cervical Cancer
Switching its focus to second-line therapy for metastatic cervical cancer, the panel reviews an unmet need of effective therapy in this setting.
Metastatic Cervical Cancer: Interpreting Data From KEYNOTE-826
Experts take a closer look at the data points from KEYNOTE-826 to consider pembrolizumab’s potential role in metastatic cervical cancer management.
KEYNOTE-826: Immune Checkpoint Inhibition in Metastatic Cervical Cancer
Considerations for the KEYNOTE-826 trial, which tested pembrolizumab in combination with chemotherapy in patients with metastatic cervical cancer.
Chemotherapy and Antiangiogenesis Therapy in Metastatic Cervical Cancer
Looking at the current treatment landscape in metastatic cervical cancer, experts consider the role of frontline chemotherapy and antiangiogenesis therapy.
Ongoing Clinical Trials in Locally Advanced Cervical Cancer
Closing out their discussion on locally advanced cervical cancer, panelists discuss ongoing clinical trials and the potential of the involved novel therapies.
Locally Advanced Cervical Cancer: Interpreting the OUTBACK Trial
Considerations for the negative results of the OUTBACK trial, which tested adjuvant chemotherapy in locally advanced cervical cancer.
Locally Advanced Cervical Cancer: Surgery and Standard of Care Therapy
Focusing on locally advanced cervical cancer, experts elucidate the role of surgery and standard of care therapy.
What is the Current Role of Biomarker Testing in Cervical Cancer?
The panel reflects on the current, optimal use of biomarker testing to guide the management of cervical cancer.
Role of HPV Vaccination and Screening to Prevent Cervical Cancer
A comprehensive review of the current paradigm for HPV vaccination and screening to prevent cervical cancer.
Understanding the Biology and Staging of Cervical Cancer
Experts provide a brief overview of cervical cancer, focusing on the driving biology and FIGO staging system.
Dr. Monk on Transformative KEYNOTE-826 Data in Frontline Cervical Cancer
Bradley J. Monk, MD, FACS, FACOG, discusses outcomes with pembrolizumab plus chemotherapy in patients with recurrent or metastatic cervical cancer, as reported in the phase 3 KEYNOTE-826 trial.
Dr. Monk on the Utility of PARP Inhibitors as Maintenance Therapy in Ovarian Cancer
Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as maintenance therapy in ovarian cancer.
Dr. Monk on the Mechanism of Action of VB-111 in Ovarian Cancer
Bradley Monk, MD, FACOG, FACS, discusses the mechanism of action of VB-111 in patients with ovarian cancer.
Dr Graff on the Relation Between ctDNA Positivity and Disease Recurrence in HR+/HER2– Breast Cancer
Dr Damodaran on Futibatinib Plus Fulvestrant in FGFR1-Amplified HR+/HER2– Breast Cancer
Trastuzumab Deruxtecan Plus Endocrine Therapy Demonstrates Antitumor Activity in HER2-Low/HR+ Metastatic Breast Cancer
T-DXd Yields Early Activity in HER2+/HER2-Low Breast Cancer With Leptomeningeal Carcinomatosis
2 Clarke Drive Cranbury, NJ 08512